A treatment for Mr WP: thiazolidinediones after troglitazone.
Montague
C T
CT
Cardiovascular & Gastrointestinal Discovery Department, AstraZeneca Pharmaceuticals, Mereside, Alderley Park, UK.
D000368:Aged; D000818:Animals; D015992:Body Mass Index; D002839:Chromans / Q000008:administration & dosage* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007333:Insulin Resistance; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity; D018160:Receptors, Cytoplasmic and Nuclear / Q000172:deficiency / Q000502:physiology; D013844:Thiazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000172:deficiency / Q000502:physiology; D000077288:Troglitazone
D002839:Chromans; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077288:Troglitazone; C089946:2,4-thiazolidinedione